PMID- 30762807
OWN - NLM
STAT- MEDLINE
DCOM- 20190314
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 7
DP  - 2019 Feb
TI  - Surveillance of non-muscle invasive bladder cancer using fluorescence in situ 
      hybridization: Protocol for a systematic review and meta-analysis.
PG  - e14573
LID - 10.1097/MD.0000000000014573 [doi]
LID - e14573
AB  - BACKGROUND: To evaluate the diagnostic effectiveness and predictive value of 
      fluorescence in situ hybridization (FISH) in the surveillance of non-muscle 
      invasive bladder cancer (NMIBC). METHODS: PubMed/Medline, EMBASE, Web of Science, 
      Ovid, Web of Knowledge, and Cochrane Library will be searched for studies related 
      to the topic. The identification, inclusion, and exclusion flowcharts will be 
      conducted according to preferred reporting items for systematic reviews and 
      meta-analysis guidelines. The identified reports will be critically appraised 
      according to the Newcastle-Ottawa scale, quality assessment of diagnostic 
      accuracy studies-2 and standards for reporting of diagnostic accuracy 2015. 
      Forest plots will be generated to display hazard ratios, sensitivities, and 
      specificities. Pooled estimates with their 95% confidence intervals will be 
      calculated using the bivariate model, the hierarchical summary receiver operating 
      characteristic model and a fixed- or random-effects model. RESULTS: This study 
      will provide evidence and data to form a comprehensive understanding of the value 
      of FISH in the surveillance of NMIBC. CONCLUSION: The diagnostic efficacy of FISH 
      will be affected by post-therapy factors. However, FISH still could facilitate 
      the surveillance of NMIBC owing to its non-invasive feature. This study will 
      improve the clinical decision-making and enlighten the future research of NMIBC.
FAU - Lin, Tianhai
AU  - Lin T
AD  - Department of Urology, Institute of Urology.
AD  - Key Laboratory of Transplant Engineering and Immunology, West China Hospital.
FAU - Jin, Hongyu
AU  - Jin H
AD  - West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
FAU - Gong, Lina
AU  - Gong L
AD  - Department of Urology, Institute of Urology.
FAU - Yu, Ruichao
AU  - Yu R
AD  - Department of Pathophysiology and Molecular Pharmacology, Joslin Diabetes Center.
FAU - Sun, Sheng
AU  - Sun S
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
FAU - Yang, Lu
AU  - Yang L
AD  - Department of Urology, Institute of Urology.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Urology, Institute of Urology.
FAU - Han, Ping
AU  - Han P
AD  - Department of Urology, Institute of Urology.
FAU - Cheng, Jingqiu
AU  - Cheng J
AD  - Key Laboratory of Transplant Engineering and Immunology, West China Hospital.
FAU - Liu, Liangren
AU  - Liu L
AD  - Department of Urology, Institute of Urology.
FAU - Wei, Qiang
AU  - Wei Q
AD  - Department of Urology, Institute of Urology.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Disease Progression
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local
MH  - *Research Design
MH  - Survival Analysis
MH  - Urinary Bladder Neoplasms/*pathology
PMC - PMC6408111
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/02/15 06:00
MHDA- 2019/03/15 06:00
PMCR- 2019/02/15
CRDT- 2019/02/15 06:00
PHST- 2019/02/15 06:00 [entrez]
PHST- 2019/02/15 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
PHST- 2019/02/15 00:00 [pmc-release]
AID - 00005792-201902150-00084 [pii]
AID - MD-D-18-09919 [pii]
AID - 10.1097/MD.0000000000014573 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Feb;98(7):e14573. doi: 10.1097/MD.0000000000014573.